Metoprolol
Treatment for Hypertension
Typical Dosage: 25-200mg daily (extended release)
Effectiveness
80%
Safety Score
65%
Clinical Trials
83
Participants
300K
Comparative Safety Scale(Higher is safer)
Cyanideā ļø
Methš
Cigarettesš¬
Chemoā¢ļø
Alcoholšŗ
Morphineš
Antibioticsš
Tylenolš
Exerciseš
Waterš§
65
DangerousModerateSafe
Treatment Details
Dosage Range
25-200mg daily (extended release)
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
50(Treat 50 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$100
Side Effect Mgmt:$75
Total Annual:$205
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$12,000/QALY
QALYs Gained
0.45
Outcome-Based Costs
Cost per Responder
$410
Comparison vs No treatment
Cost Difference
$-205/year
Less expensive
QALY Difference
+0.45 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Metoprolol Outcomes
for Hypertension
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+50%
Common Side Effects
Fatigue
+15%
Bradycardia
+8%
Dizziness
+7%
Erectile dysfunction
+5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
12 completed trials for Metoprolol in Hypertension
Factorial Study of Metoprolol Succinate TOPROL-XL (324A)
NCT00642096COMPLETEDPHASE3
1.9K participants
INTERVENTIONAL
Started: Jun 1, 2003
Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life
NCT00999102COMPLETEDPHASE4
37 participants
INTERVENTIONAL
New York, United States
Started: Oct 1, 2009
307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XLĀ® in Hypertensive Pediatric Subjects
NCT00255502COMPLETEDPHASE3
100 participants
INTERVENTIONAL
Little Rock, United States +30 more
Started: Jul 1, 2002
The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
NCT01049009COMPLETEDPHASE4
91 participants
INTERVENTIONAL
Atlanta, United States
Started: Dec 1, 2009
Dose Ranging, Safety and Tolerability of TOPROL-XLĀ® Extended-Release Tablets in Hypertensive Pediatric Subjects
NCT00255528COMPLETEDPHASE3
144 participants
INTERVENTIONAL
Little Rock, United States +30 more
Started: Jul 1, 2002
Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients
NCT01508325COMPLETEDPHASE4
186 participants
INTERVENTIONAL
Changsha, China
Started: Dec 1, 2011
Pharmacogenomic Evaluation of Antihypertensive Responses 2
NCT01203852COMPLETEDPHASE4
839 participants
INTERVENTIONAL
Gainesville, United States +2 more
Started: Aug 1, 2010
Nebivolol Versus Metoprolol: Sodium Sensitivity
NCT00992056COMPLETEDPHASE4
24 participants
INTERVENTIONAL
Miami, United States
Started: Dec 1, 2010
Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function
NCT01248338COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Tartu, Estonia
Started: Mar 1, 2006
Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells
NCT01041287COMPLETEDPHASE4
96 participants
INTERVENTIONAL
Atlanta, United States
Started: Dec 1, 2009
Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function
NCT00995072COMPLETEDNA
29 participants
INTERVENTIONAL
Jacksonville, United States
Started: Oct 1, 2009
Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients
NCT01157234COMPLETEDPHASE4
32 participants
INTERVENTIONAL
Gainesville, United States
Started: Jul 1, 2010
Showing 20 of 84 total trials